Sector Watch: Healthcare - May 17 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $107.59 +0.06 0.06% | XBI: $93.78 +0.31 0.33% | Updated May 17, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| EIGR52WH Eiger BioPharmaceuticals $163.4M |
16.80+4.95 1.3 M 14.3x |
42% | ||
| LOXO52WH Loxo Oncology $5.1B |
167.53+28.03 2.7 M 7.5x |
20% | ||
| BDSI BioDelivery Sciences International $134.4M |
2.30+0.35 1.9 M 6.8x |
18% | ||
| VTVT VTv Therapeutics $61.3M |
1.81+0.24 2.9 M |
15% | ||
| NERV Minerva Neurosciences Inc $293.4M |
7.40+0.90 493.4 K 3.6x |
14% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals $217.7M |
8.61-2.51 1.6 M 6.6x |
-23% | ||
| DVAX Dynavax Technologies $1.0B |
16.70-2.65 5.9 M 3.4x |
-14% | ||
| NKTR Nektar Therapeutics $13.2B |
79.23-6.57 5.3 M 2.2x |
-8% | ||
| CYAD52WL Celyad SA $278.9M |
26.05-2.15 178.4 K 36.4x |
-8% | ||
| ONCS OncoSec Medical $81.6M |
1.65-0.13 2.8 M 2.3x |
-7% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Celyad Announces Pricing of $47.3 Million Global Offering | Business Wire [businesswire.com]Bayer Highlights Latest Oncology Research at ASCO 2018 [prnewswire.com]
Celyad announces pricing of $47.3 million global offering [globenewswire.com]
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing [globenewswire.com]
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business [globenewswire.com]
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia [globenewswire.com]
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with [prnewswire.com]
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) [prnewswire.com]
Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society [prnewswire.com]
Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [prnewswire.com]
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the [prnewswire.com]
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting [prnewswire.com]
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [globenewswire.com]
Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions, Plug Power, GameStop, and Newfield Exploration ? Emerging Consolidated Expectations, Analyst Ratings [globenewswire.com]
vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights | Business Wire [businesswire.com]
Celyad Announces Launch of Proposed Global Offering | Business Wire [businesswire.com]
Celyad Announces First Quarter 2018 Business Update [globenewswire.com]
Celyad announces launch of proposed global offering [globenewswire.com]
Biotech Sector Volatile Ahead of Trump Announcement [prnewswire.com]
MSCI Equity Indexes May 2018 Index Review | Business Wire [businesswire.com]
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update [globenewswire.com]
Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results [prnewswire.com]
BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update [globenewswire.com]
Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 [prnewswire.com]
Experienced Biotech Executive and Scientific Leader Dr. Stephen Harrison Joins Engine Biosciences [prnewswire.com]
Experienced Biotech Executive and Scientific Leader Dr. Stephen Harrison Joins Engine Biosciences as Chief Scientific Officer and Senior Vice President [prnewswire.com]
vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June | Business Wire [businesswire.com]
Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference [prnewswire.com]
Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 [prnewswire.com]
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018 [globenewswire.com]
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and [prnewswire.com]
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update [prnewswire.com]
Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences [globenewswire.com]
Loxo Oncology Reports First Quarter 2018 Financial Results [globenewswire.com]
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class [prnewswire.com]
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus [prnewswire.com]
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer [prnewswire.com]
Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [globenewswire.com]
Dynavax Reports First Quarter 2018 Financial Results Nasdaq:DVAX [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
